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Extracellular deposition of β amyloid plaques is an early event associated to
Alzheimer’s disease. Here, we have used in vivo gadolinium-stained high resolution
(29∗29∗117 µm3) magnetic resonance imaging (MRI) to follow-up in a longitudinal
way individual amyloid plaques in APP/PS1 mice and evaluate the efficacy of a new
immunotherapy (SAR255952) directed against protofibrillar and fibrillary forms of Aβ.
APP/PS1 mice were treated for 5 months between the age of 3.5 and 8.5 months.
SAR255952 reduced amyloid load in 8.5-months-old animals, but not in 5.5-months
animals compared to mice treated with a control antibody (DM4). Histological evaluation
confirmed the reduction of amyloid load and revealed a lower density of amyloid plaques
in 8.5-months SAR255952-treated animals. The longitudinal follow-up of individual
amyloid plaques by MRI revealed that plaques that were visible at 5.5 months were
still visible at 8.5 months in both SAR255952 and DM4-treated mice. This suggests that
the amyloid load reduction induced by SAR255952 is related to a slowing down in the
formation of new plaques rather than to the clearance of already formed plaques.
Keywords: Alzheimer, amyloid, gadolinium, immunotherapy, MRI
INTRODUCTION
Alzheimer’s disease (AD) is the most common neurodegenerative disease of the central nervous
system. It is characterized by two major microscopic lesions: β amyloid deposits in the form
of extracellular amyloid β (Aβ) plaques and neurofibrillary tangles (NFTs) made of abnormal
intracellular tau protein aggregates (Braak and Del Tredici, 2015). Aβ is constantly produced in
the human brain where it normally remains in a soluble state (Haass and Selkoe, 2007; Eisele,
2013). However, Aβ peptides can adopt alternative conformations that aggregate into oligomeric,
then proto-fibrillar and finally fibrillar forms that constitute the amyloid plaques (Eisele, 2013).
Oligomeric Aβ induces synaptic toxicity (Lacor et al., 2004), while amyloid plaques lead to
neuroinflammation (Serpente et al., 2014) and are also a reservoir for toxic soluble forms of Aβ
(Craft et al., 2002). Limiting the amyloid load in the brain is therefore a potential therapeutic
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strategy for AD. Active and passive Aβ immunotherapy is the
principle that has come furthest, both in number and in stage
of clinical trials. These therapies can be efficient via a large
number of mechanisms of action (Fu et al., 2010; Wisniewski
and Goni, 2015). However, major difficulties have been reported
in identifying clinical benefits in clinical trials initiated in
symptomatic phases of the disease. They could be explained by
the late initiation of the trials and a consensus is that future trials
need to be performed in very early stages of the disease. This
strategy is supported by recent data suggesting that a regionally
limited tauopathy precedes Aβ pathology and in order to spread
to the whole brain, the tau pathology requires the concomitant
presence of Aβ pathology (Delacourte et al., 2002; Jack et al.,
2013; Braak and Del Tredici, 2015). Refinements of anti-amyloid
immunotherapies are ongoing to develop new therapies with
mechanisms of action that improve their efficiency and reduce
potential side effects when tested in young subjects (Wisniewski
and Goni, 2015).
In vivo imaging of amyloid plaques is useful to evaluate anti-
amyloid therapies and/or mechanisms associated with amyloid
plaque production either at the clinical or preclinical levels.
In humans, in vivo neuroimaging studies of amyloid plaques
are performed with Positron emission tomography (PET) using
different PET ligands (Nordberg, 2007). However, the low spatial
resolution of PET does not allow the visualization of individual
plaques. In animals, PET studies have provided controversial
results (Klunk et al., 2005; Maeda et al., 2007) and, to date,
PET has not been used to monitor anti-amyloid therapies.
Other imaging modalities, such as optical imaging (Hintersteiner
et al., 2005) or two-photon imaging after craniotomy (Dorostkar
et al., 2014), have also been developed to detect amyloid
plaques in animals. As PET, optical imaging does not detect
individual plaques. On the contrary, two-photon imaging can
reveal individual amyloid plaques at very high resolution (1 µm).
It can detect plaques localized underneath a skull open window
using non-destructive multiphoton laser excitation and images
can be efficiently acquired from cortical surface up to 800 µm of
depth. The field of view of the technique is limited and does not
allow to record images from the whole brain as this would require
large craniotomies (Delatour et al., 2010).
Continuous efforts are also ongoing to implement amyloid
plaque detection by magnetic resonance imaging (MRI; Poduslo
et al., 2002; Zaim Wadghiri et al., 2003; Higuchi et al., 2005;
Sigurdsson et al., 2008). MRI-based monitoring of amyloid
plaques can be divided into three research fields. Some methods
are based on the natural contrast of the plaques that appear as
dark spots in T2, T2∗-weighted (T2∗w; Jack et al., 2005; Dhenain
et al., 2009) or susceptibility-weighted images (Chamberlain et al.,
2009) due to the presence of iron in the core of these lesions.
However, in humans the possibility to detect iron within plaques
is still controversial (Dhenain et al., 2002; Meadowcroft et al.,
2009; Zeineh et al., 2015). In addition, iron accumulation in
mice mainly occurs in old animals, which makes amyloid plaque
detection and pharmacology studies using this method very
challenging in young animals. The use of MR contrast agents
targeting amyloid plaques provides another option to detect these
lesions. These agents modulate the MR signal of the plaques and
increase their contrast with the brain parenchyma (Poduslo et al.,
2002; Zaim Wadghiri et al., 2003; Higuchi et al., 2005; Sigurdsson
et al., 2008). The third option to detect amyloid plaques by in vivo
MRI is to use non-targeted contrast agents (Petiet et al., 2012).
In that case, the non-targeted agents increase the signal of brain
tissues that surround the plaques. As the volume of brain tissue
is high, as compared to the volume of the plaques, these agents
induce a high signal increase in the brain. This latter can be
converted into resolution enhancement in order to record high
resolution images.
The ability to use MR imaging to follow-up anti-amyloid
therapies is still an opened question. Two studies showed that
ex vivo MRI can be used to evaluate the impact of memantine
or coenzyme Q10 on amyloid load (Scholtzova et al., 2008; Yang
et al., 2011), but to our knowledge no study evaluated the ability
of MRI to follow-up in vivo and in a longitudinal way the impact
of anti-amyloid therapies on amyloid load. Here, we used Gd-
stained MRI to monitor, in a longitudinal study, the efficacy of a
passive immunotherapy (SAR255952).
SAR255952 is a mouse monoclonal aglycosylated IgG1
antibody engineered to reduce the risk of vasogenic edemas and
microhemorrhages that have been associated to anti-amyloid
immunotherapies (Pradier et al., 2013). These potential side
effects of immunotherapies have been revealed by clinical
trials that highlighted signal changes on MR images [also
called amyloid imaging related abnormalities (ARIA); Sperling
et al., 2011]. SAR255952 was designed on the basis of an
antibody (13C3) that binds to soluble protofibrillar and fibrillar
forms of Aβ (Schupf et al., 2008), the most synaptotoxic
forms of Aβ (Haass and Selkoe, 2007). 13C3 do not target
soluble Aβ monomers or low molecular weight Aβ complexes
(Schupf et al., 2008), which limits peripheral sink effects
that can lead to microhemorrhages (Pradier et al., 2013).
SAR255952 is an aglycosyled form of 13C3. The rationale for
this aglycosylation is based on the fact that classical anti-
amyloid monoclonal glycosylated antibodies can induce Fc-γ
receptor-mediated overactivation of microglial cells as well as
activation of the complement pathway that may contribute to
an inappropriate proinflammatory response leading to vasogenic
edemas or cerebral microhemorrhages (Lue and Walker, 2002;
Adolfsson et al., 2012). These effector functions of antibodies are
linked to their glycosylated states (Jefferis, 2009). Aglycosylation
limits the activation of Fc-γ receptors and C1q component
of complement and preclude the risk of vasogenic edemas
and microhemorrhages (Pradier et al., 2013). A phase 1
clinical trial is ongoing using a humanized version of this
antibody1.
Transgenic mouse models of amyloidosis were treated
between the age of 3.5 and 8.5 months and were imaged by
MRI twice at 5.5 and 8.5 months. Gd-stained longitudinal MRI
allowed to follow-up individual amyloid plaques from 5.5 to
8.5 months and revealed that plaques that were visible at the first
time point were still detected at the second time point. Also, MRI,
as well as histology, showed a reduction of amyloid load in the
SAR255952-treated animals.
1http://www.alzforum.org/therapeutics/sar228810
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MATERIALS AND METHODS
Animals
Experiments were conducted on female APP/PS1 (n = 26)
and PS1 (n = 20) transgenic mice overexpressing amyloid
precursor protein (APP) and/or presenilin 1 (PS1) mutations
associated with familial AD [double Thy1 APP751SL Swedish
(KM670/671NL) and London (V717I) mutations introduced in
the human APP751 sequence] × HMG PS1M146L transgenic
mouse line (Blanchard et al., 2003; Delatour et al., 2006). The
PS1 mice were littermates of the APP/PS1 mice. In APP/PS1
mice, amyloid deposition starts at the age of 2.5 months
(Blanchard et al., 2003). PS1 animals are amyloid free. Animal
experimental procedures were performed in strict accordance
with the recommendations of the EEC (86/609/EEC) and
the French national committee (decree 87/848) for the care
and use of laboratory animals. The research was conducted
under the authorization number 91–326 from the “Direction
Départementale des Services Vétérinaires de l’Essonne.”
Passive Immunization
Animals were passively immunized weekly by intraperitoneal
(IP) injections of a mouse monoclonal aglycosylated IgG
antibody [SAR255952, 10 mg/kg (diluted in PBS)]. Age-matched
control mice received weekly intraperitoneal injections of a
control antibody that does not recognize murine antigens [DM4,
10 mg/kg (diluted in PBS), IP]. Four groups of mice were used:
(1) APP/PS1 mice immunized with the SAR255952 antibody
(n = 14); (2) APP/PS1 mice immunized with the control DM4
antibody (n= 12); (3) PS1 mice immunized with the SAR255952
antibody (n = 10) and (4) PS1 mice immunized with the
control DM4 antibody (n = 10). All animals were 3.5-months-
old at the beginning of the immunization and were treated for
5 months, i.e., until 8.5 months. The PS1 amyloid-free animals
survived during the whole study while mortality was higher
in the APP/PS1 mice (Supplementary Figure S1). All the mice
were imaged by MRI at 2 and 5 months after the beginning
of the treatment, i.e., at 5.5 and 8.5 months-old. We did not
perform any baseline MRI (at 3.5 months) as we knew from
previous experiments that amyloid plaques cannot be detected by
MRI at this age. The mice were sacrificed after the second MRI
exam.
In Vivo Detection of Amyloid Plaques by
MRI
Detection of amyloid plaques was based on the administration
of a gadolinium derivative contrast agent, gadoterate meglumine
(Gd-DOTA, Dotarem R©, Guerbet, France), to the animals as
previously described (Petiet et al., 2012; Santin et al., 2013).
The contrast agent can be administered either intracerebro-
ventricularly (Petiet et al., 2012) or intravenously combined with
ultrasound-induced blood–brain barrier (BBB) opening (Santin
et al., 2013). As BBB opening with ultrasound was recently shown
to reduce amyloid load (Jordao et al., 2013), we opted for the
intracerebro-ventricular administration of Gd rather than IV
combined with ultrasound-induced BBB opening. Briefly, the
mice were anesthetized with a mixture of isoflurane (1–2%) and
air (1 L/min). They were then placed on a stereotaxic frame and
the MR contrast agent was injected into the lateral ventricles at
coordinates A/P −0.2 mm, L ± 1 mm, −1.8 mm relative to the
surface of the dura mater (Paxinos and Franklin, 2001) by using
Hamilton syringes (26 s gauge). A volume of 1 µl (0.5 mmol/mL,
i.e., 0.02 mmol/kg) was injected into each hemisphere at a rate
of 0.2 µl/min. In vivo MRI was performed on a 7T-spectrometer
(Agilent, USA) interfaced with a console running VnmrJ 2.3.
The spectrometer was equipped with a rodent gradient insert of
700 mT/m. A birdcage coil (RapidBiomed, GmbH, Germany) was
used for emission and an actively decoupled mouse brain surface
coil (RapidBiomed GmbH, Germany) was used for reception.
MR images were recorded using a high-resolution 3D-Gradient
Echo sequence with a resolution of 29∗29∗117 µm3 (field of
view: 15∗15∗15 mm3, matrix = 512∗512∗128, TR = 50 ms,
TE = 25 ms, flip angle = 20◦, number of averages = 2,
bandwidth = 25 kHz, acquisition time: 1 h 49 min). MR images
were recorded starting at 60 min after administration of the Gd-
DOTA contrast agent used for Gd-staining. During the MRI
experiment the animals were anesthetized with a mixture of
isoflurane (0.75–1.5%) and carbogen (95% O2 – 5% CO2) and
their breathing rate was monitored. Carbogen was used to reduce
the signal coming from the circulating blood (Thomas et al.,
2003).
Amyloid Load Quantification from MR
Sections
Magnetic resonance images were filtered with a kernel defined in
matrix form as 1 1 1; 1 8 1; 1 1 1 with ImageJ freeware (Schindelin
et al., 2012). Then cortical amyloid load was calculated by using
a method similar to that reported by Jack et al. (2005) and
Santin et al. (2013). Briefly, eight coronal slices (antero-posterior
direction), evenly spaced by 468 µm, were selected and four
circular ROIs (surface∼1 mm2 each) were drawn on each of these
slices (two in each hemisphere; ImageJ freeware, Figures 1C,D).
The eight slices were positioned so that the third slice was
localized at the level of the anterior commissure. The coordinates
of the first and last slices were thus 1.08 and −2.2 mm compared
to the Bregma (Paxinos and Franklin, 2001). Hypointense spots
were manually outlined, excluding hypointense elements that
could be followed over more than two adjacent slices, or that
had a tube-like shape, suggesting the presence of a blood vessel.
Plaque load corresponded to the ratio of the mean area of
hypointense spots measured in each ROI over the surface of
the ROI.
Neuropathology
After the last MRI, the animals received an injection of
pentobarbital. They were then perfused by intracardiac injection
with PBS 0.01 M SIGMA + Heparin 5000 units/L and 10%
neutral buffered formalin (PB 0.1 M) using a peristaltic pump
(flow rate∼2 mL/min). The brains were then carefully extracted,
post-fixed in formalin for 24-h at 4◦C and finally stored in PBS
at 4◦C.
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The brains were then processed by NeuroScience Associates2
in order to perform histological analysis. Formalin-fixed brains
were frozen and cut along the rostro-caudal axis. Five series
of 25-µm-thick coronal sections were collected. The first,
second and third series were used for Nissl staining, Aβ
peptide deposits staining (6E10 monoclonal antibody IHC),
and immunoglobulin G (IgG) staining (antimouse secondary
antibodies IHC), respectively. A flatbed scanner (ImageScanner
III, G.E. Healthcare) was used to digitize all stained series (lateral
2www.neuroscienceassociates.com
FIGURE 1 |Continued
FIGURE 1 | Continued
Modulation of amyloid load following immunotherapy with SAR255952
or DM4 monoclonal antibodies. Registration between MR images (A) and
amyloid-stained histological sections (B; 6E10 immunohistochemistry) in an
8.5-months-old APP/PS1 mouse. Hypointense spots observed on the MR
images at the level of the cortex (Ctx) and hippocampus (Hip; A) are localized
with amyloid plaques detected on the histological sections (B). ROIs used for
plaque counting displayed on MR images of an APP/PS1 mouse at the age of
5.5 (C) and 8.5 months [D; A/P level = −2.2 mm compared to the Bregma
(Paxinos and Franklin, 2001)]. (E) Measures from MR sections revealed an
increased amyloid load between 5.5 and 8.5 months in SAR255952 and DM4-
treated animals (repeated measure ANOVA and post hoc analysis within each
group F [1,11] = 23 and 29, respectively, ∗∗∗p < 0.001). At 8.5 months, the
amyloid load was lower in SAR255952-treated animals (n = 9) compared to
control DM4-treated mice (n = 4; repeated measure ANOVA and post hoc
analysis F [1,11] = 7, ∗p = 0.02). Histological measures confirmed the lower
amyloid load [F, Student’s t-test, t(10) = 2.3, ∗p = 0.04] and reduced density
of amyloid plaques [G, t(10) = 2.7, ∗p = 0.02] in SAR255952-treated animals
at 8.5 months. The average size of the amyloid plaques was not modulated by
therapy [H, t(10)= 0.6, ns]. Amyloid load in (E,F) is expressed as the proportion
(%) of tissue area occupied by hypointense spots (E) or 6E10 immunoreactivity
(F). Scale bars: 1 mm. Error bars represent standard error of the mean.
resolution: 5 µm for sections Aβ- and IgG-stained sections).
Thus, for each stain, 80 sections, evenly spaced by 125 µm across
the entire cerebrum were digitized.
Amyloid plaques and IgG staining were quantified from
histological sections by using ImageJ and a protocol similar to
that used to quantify plaques from MRI: eight coronal slices
stained with 6E10 or anti-IgG, evenly spaced by 500 µm, were
selected and four circular ROIs (surface ∼1 mm2 each) were
drawn on each of these slices (two in each hemisphere). Each
stained section was binarized after conversion of the images into
gray scale images and thresholded. Amyloid plaques were further
segmented by using a watershed algorithm. The proportion of
tissue area occupied by 6E10 or anti-IgG immunoreactivity, as
well as the number of amyloid plaques and their average sizes
were quantified within each ROI by using the “area fraction”
and “analyze particles” tools of the imageJ measurement process.
The ratio (stained surfaces/ROI surfaces) was taken as a global
measure of the cerebral “amyloid load” or “IgG load” of each
individual mouse. Thus, for each staining, 64 observations were
performed for each animal.
Correlation between In Vivo MRI and
Histology
Longitudinal MR images and histological sections for a given
animal were registered by using BrainVisa freeware3 (Dubois
et al., 2010). A rigid registration was performed to register MR
images recorded at 8.5 months onto MR images recorded at
5.5 months.
Statistical Analysis
Statistical analysis was performed using Statistica 7 software
(Statsoft, France). The significance of between-group differences
was tested by repeated measures ANOVA for longitudinal
study and Student’s t-test for post mortem measures.
3http://brainvisa.info
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Correlation studies were based on Pearson’s correlation
coefficient. Statistical significance was set to p < 0.05. Results
are expressed in figures as mean ± standard error of the
mean (SEM).
RESULTS
Detection of Amyloid Plaques by
Gd-Stained MRI
Three-dimensional MR images of APP/PS1 and PS1 mice were
recorded with a resolution of 29∗29∗117 µm3. Hypointense spots
were seen in the cortex (Figures 1A and 2A–D), hippocampus
(Figure 1A), thalamus and septal nuclei of transgenic APP/PS1
mice after Gd-staining protocols. No hypointense spots were
observed in the brain of PS1 amyloid-free mice at 5.5 and
8.5 months (Figures 2E,F). Registration between MR images and
histological sections confirmed that the hypointense spots on MR
images were amyloid plaques (Figures 1A,B).
Longitudinal Monitoring of Amyloid
Plaques and Treatment Effects
APP/PS1 mouse models of amyloidosis were passively
immunized with SAR255952 or with a control (DM4) antibody
from 3.5 months old until 8.5 months-old. The mice were
followed-up in a longitudinal way and MR images were recorded
2 and 5 months after the beginning of the treatment, i.e., at 5.5
and 8.5 months-old. For each animal, we registered MR images
recorded at 5.5 and 8.5 months in order to monitor the evolution
of each hypointense spots corresponding to amyloid plaques.
The visual observation of these images revealed an age-related
increased in amyloid load in both DM4 (Figures 2A,B) and
SAR255952-treated animals (Figures 2C,D). In both treatment
groups the plaques that were present in 5.5-months-old animals
were still present at 8.5 months (Figures 2A–D – yellow
arrows). Some new plaques occurred between the age of 5.5 and
8.5 months (Figures 2A–D – red arrows).
Quantitative studies of MRI sections revealed a similar
amyloid load in the 5.5-months-old animals treated with DM4 or
SAR255952 antibodies (n.s., Figure 1E). Amyloid load increased
in both DM4 and SAR255952-treated animals between the ages
of 5.5–8.5 months (from 3.4 ± 0.6% to 7.5 ± 0.2% and from
3.3 ± 0.3% to 5.7 ± 0.4% in DM4 and SAR255952-treated
mice, respectively, p < 0.001, Figure 1E). At 8.5 months,
the amyloid load detected by MRI was 24% lower in the
SAR255952-treated mice compared to the DM4-treated mice
(p = 0.02, Figure 1E). Histological evaluations confirmed the
lower amyloid load in 8.5-months-old APP/PS1 animals treated
with SAR255952 compared to animals treated with the control
antibody (15.8± 2.0% versus 10.6± 1.1%, respectively, p= 0.04,
Figure 1F). In addition, histological quantifications revealed that
the number of amyloid plaques (plaque density) was reduced
by 33% in the SAR255952-treated animals compared to the
DM4-treated animals (p = 0.02, Figure 1G), whereas the size
of the plaques was not significantly different in the two groups
(Figure 1H).
Relationship with Immunoglobulin and
Amyloid Load in the Brain
We stained IgG deposition in the brain to further evaluate
the interaction between IgG and amyloid. In SAR255952-
treated animals, IgG decorated amyloid plaques from all the
brain regions examined (Figures 3A,C) while we did not
detect any plaques labeled by IgG in the DM4-treated animals
(Figures 3B,C). The quantification of IgG in brain sections
spreading from the anterior to the posterior parts of the brain
showed that IgG was equally distributed on all the brain sections
(Figure 3C). There was also a strong positive correlation between
the IgG load and the amyloid load (r = 0.90, p = 0.002,
Figure 3D) or amyloid density (r = 0.85, p = 0.007, Figure 3E)
detected by histology.
DISCUSSION
The formation of amyloid plaques is one of the major
neuropathological hallmarks of AD. Limiting the amyloid load
in the brain is therefore a potential therapeutic strategy against
this disease. Anti-amyloid immunotherapies are the approaches
that have come furthest to limit cerebral amyloidosis. Current
refinements of these therapies aim to improve their efficiency
and reduce potential side effects. Methods of in vivo amyloid
plaques detection are drug development tools that are critical to
speed the development of these new therapies (U.S. department
of health and human services et al., 2014). PET (Nordberg,
2007) or optical imaging (Hintersteiner et al., 2005) can be
used to quantify amyloid load but these methods cannot detect
individual plaques. On the contrary, several MRI approaches
have been developed to detect individual amyloid plaques,
but none of them were used to follow-up a therapy in vivo
and in a longitudinal way. Some methods are based on the
natural contrast of the plaques (Jack et al., 2005; Chamberlain
et al., 2009). Some others use targeted MR contrast agents
that modulate the MR signal of the plaques and increase the
contrast between the plaques and the brain parenchyma (Poduslo
et al., 2002; Zaim Wadghiri et al., 2003; Higuchi et al., 2005;
Sigurdsson et al., 2008). Here, we used a third method, called
Gd-staining, based on non-targeted contrast agents. One of
the advantages of the Gd-staining protocol is that it allows to
record images with a much better resolution and contrast than
without or with targeted contrast agents, as it is based on the
distribution of the agents within the brain parenchyma and
not into the plaques. We showed that Gd-stained MRI is able
to detect amyloid plaques in vivo with a very high resolution
(29 µm × 29 µm × 117 µm). It can be used to monitor
individual amyloid plaques in the whole brain and to assess
the dynamics of their formation and clearance. Interestingly,
we were able to demonstrate the very long stability (3 months)
of plaques already deposited in the brain. One can argue that
the registration of amyloid plaques detected from Gd-stained
MRI and immunohistochemical sections was not perfect. This
might be related to limitations in the precision of co-registration
because of the different thickness of immunohistochemical
(25 µm) and MRI sections (117 µm). This can also be related
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FIGURE 2 | Longitudinal follow-up of DM4 and SAR255952 treatments by MR imaging in APP/PS1 and PS1 mice. DM4 (A,B) and SAR255952-treated
(C,D) APP/PS1 mice and DM4-treated PS1 amyloid-free mice (E,F) were imaged by MRI at the age of 5.5 (A,C,E) and 8.5 months (B,D,F). Hypointense spots
corresponding to amyloid plaques were visible in the APP/PS1 mice (A–D), but not in the PS1 animals (E,F). MR images from the same animals were registered to
follow-up these hypointense spots between 5.5 and 8.5 months. In both DM4 (A,B) and SAR255952-treated (C,D) APP/PS1 mice the plaques detected at
5.5 months were still visible at 8.5 months (yellow arrows). Some new plaques occurred between the age of 5.5 and 8.5 months (red arrows). No plaques were
detected in PS1 mice at 5.5 or 8.5 months. Typical landmarks, such as blood vessels are shown with green arrows. Some plaques that were slightly visible at
5.5 months and which were more visible at 8.5 months are labeled with pale yellow arrows. S-Ctx, somatosensory cortex; Cg-Ctx, cingulate cortex.
to the different mechanisms leading to plaque detection by MRI
or immunohistochemistry. With Gd-stained MRI, the ability to
detect the plaques is related to their hydrophobicity (Dhenain
et al., 2006), while by immunohistochemistry it is associated
to the presence of amyloid epitopes revealed with specific
antibodies.
It is important to outline that the doses of Gd administered
to the animals were very low (0.02 mmol/kg) as compared
to doses commonly used for intra-venous administration
(0.1–0.2 mmol/kg). Also, the contrast agent that we used is
largely used in the clinic including for applications that are based
on its penetration into the brain (Anzalone et al., 2013; Saake
et al., 2016). Its safety profile is supported by post-marketing
experience from approximately 30 million doses administered
in 70 different countries since its initial approval in 1989
(Guerbet, 2013). Finally, a recent study showed that unlike
linear gadolinium-based contrast agents macrocyclic contrast
agent such as Dotarem does not accumulate in the brain even
after 20 intra-venous administration at high doses (0.6 mmol/kg;
Radbruch et al., 2015; Robert et al., 2016). The only limitation of
the Gd-staining method is that it is based on the intracerebro-
ventricular administration of the contrast agent, although this
administration way is widely used in preclinical settings. Albeit
still speculative, several procedures can be proposed to by-
pass the BBB and promote future development of Gd-staining
procedure including in humans. Gadolinium can be administered
into the subarachnoid space and reach the brain as already
demonstrated in human studies (Tali et al., 2002; Selcuk et al.,
2010). Gadolinium can also be administered intravenously in
association with BBB opening based on ultrasound technology
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FIGURE 3 | Evaluation of IgG staining in the brains of APP/PS1 mice treated with SAR255952 or DM4. IgG staining in the brains of APP/PS1 mice treated
with SAR255952 (A) or DM4 (B). IgG was only decorating amyloid plaques (black arrows) in the SAR255952-treated animals (A). (C) IgG load in the different brain
sections. The site of contrast agent administration (A/P −0.2 mm) is highlighted with a dashed line. IgG load was higher in SAR255952 compared to DM4-treated
animals. The IgG load was similar within all brain sections in SAR255952 (n = 9) or DM4-treated (n = 4) animals. (D,E) Relationship between IgG and amyloid load
(D, r = 0.90, p = 0.002) or density of amyloid load (E, r = 0.85, p = 0.007) quantified from histological sections. IgG and amyloid loads in (C–E) are expressed as
the proportion (%) of tissue area occupied by anti-IgG or 6E10 immunoreactivity. Error bars stand for standard error of the mean. Scale bars: 500 µm.
(Santin et al., 2013). Interestingly, this method of BBB opening
in currently tested in humans4. Compounds that transiently
increase BBB permeability, such as lysophosphatidic acid (LPA),
could also be administered together with gadolinium to increase
its uptake into the brain (On et al., 2013). Finally, methods based
on natural transport systems could also be used to improve the
uptake of gadolinium across the BBB. For example, a recent
study showed that fusing a single-chain Fab fragment of an
anti-transferrin receptor antibody to a molecule of interest can
increase the uptake of the molecule of interest by more than
50-fold (Niewoehner et al., 2014).
Multiple mechanisms have been involved in the efficacy of
anti-amyloid immunotherapies. For example, some of them
clear aggregated forms of Aβ (Demattos et al., 2012), whereas
others focus on inhibiting amyloid seeding to prevent amyloid
deposition propagation (Golde, 2003) or target soluble forms
of Aβ to shift the equilibrium between soluble and fibrillar
Aβ to favor plaque dissolution (DeMattos et al., 2001). The
4https://clinicaltrials.gov/ct2/show/NCT02343991
SAR255952 anti-amyloid antibody used in this study targets
both protofibrillar and fibrillar amyloid forms (Schupf et al.,
2008; Pradier et al., 2013). Our data show that IgG (presumably
SAR255952) is homogeneously distributed in the brain of
SAR255952-treated APP/PS1 mice while DM4-treated APP/PS1
mice did not display any IgG immunoreactivity. We also found
a positive relationship between the amyloid and IgG loads in the
SAR255952-treated APP/PS1 mice which is consistent with the
targeting of fibrillar amyloid forms of Aβ by SAR255952. By using
Gd-stained MRI, we were able to demonstrate the efficacy of this
anti-Aβ antibody to slow down the evolution of amyloid load.
We could also monitor individual plaques during two imaging
sessions separated by 3 months and showed that, even in the
SAR255952-treated animals, plaques that were present at the first
time point were still detected 3 months later. This suggests that
the targeting of fibrillar forms of Aβ by SAR255952 does not lead
to the clearance of the plaques. The lower amyloid load in the
SAR255952-treated animals was thus due to a decrease in the
formation of new plaques, probably related to the targeting of
protofibrillar forms of Aβ.
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On the basis of our histological study, we also reported that the
lower amyloid load in the SAR255952-treated animals was linked
to a reduction of amyloid plaque density and not to a diminution
of the size of the plaques. One explanation for this pattern of
amyloid load modulation can come from recent models showing
that, in the absence of therapy, amyloid load increases following
three temporal phases (Burgold et al., 2014). In the first phase,
the density of plaques increases while the size of the plaques is
stable. In the second phase, the size of the plaques increases while
their density remains stable. Plaque size and volume are stable in
the last phase. The modulation of the density of the plaques and
not of their size in our animals is consistent with an action of
the therapy in mice that were in the first phase of amyloid load
increase, i.e., in the phase where it is the density of the plaques
and not their size that evolves over time and indeed, the relatively
young animals involved in our study were probably in that stage
of plaque development.
CONCLUSION
We have shown that Gd-stained MR imaging can be used to
monitor individual amyloid plaques in a longitudinal way, to
test the efficacy of an anti-amyloid immunotherapy in APP/PS1
mice. This method can be used in addition to histological
evaluations as a useful tool for the development of new therapies.
Future improvement of the method may be based on the
automatic segmentation of the amyloid load to speed-up plaque
quantification after Gd-staning (Iordanescu et al., 2012). Also,
our study showed that individual plaque labeling is feasible in vivo
with a conventional MR contrast agent, as long as the contrast
agent remains furtive for the BBB.
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